BioSyent Releases Financial Results for Q2 and H1 2025

Core Insights - BioSyent Inc. reported strong financial performance for Q2 and H1 2025, with overall sales growth of 14% and net profit growth of 28% [1][5] - The Canadian Pharma segment saw a 9% increase in sales, while the International Pharma segment experienced a significant 183% increase in Q2 2025 [1][5] - The company aims for long-term value creation through portfolio diversification and profitable growth [1] Financial Performance - Total Company Sales for Q2 2025 reached CAD 10,179,296, a 14% increase compared to Q2 2024, and CAD 21,158,256 for H1 2025, reflecting a 27% increase from H1 2024 [5][9] - Net Income After Taxes for Q2 2025 was CAD 2,018,171, up 28% from Q2 2024, and CAD 4,338,104 for H1 2025, a 30% increase from H1 2024 [5][9] - EBITDA for Q2 2025 was CAD 2,760,149, representing a 35% increase year-over-year, and CAD 5,961,796 for H1 2025, a 40% increase [5][9] Balance Sheet Highlights - As of June 30, 2025, total assets increased to CAD 43,495,489, a 5% rise from December 31, 2024 [7][10] - Cash, cash equivalents, and short-term investments rose by 28% to CAD 20,364,392 [7] - Trade and other receivables increased by 67% to CAD 4,867,796, while inventory decreased by 9% to CAD 4,860,613 [7] Shareholder Returns - The company repurchased 19,500 common shares during H1 2025 under a Normal Course Issuer Bid [5] - Quarterly cash dividends of CAD 0.05 per common share were paid on March 14, 2025, and June 13, 2025, with a subsequent dividend declared for September 15, 2025 [5]